Showing results (221-230 of 240) with videos related to
Sort By:
Pageof 24
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 15, 2025
Beyond symptom improvement: transdiagnostic and disorder-specific ways to assess functional and quality of life outcomes across mental disorders in adultsChristoph U Correll, Samuele Cortese, Marco Solmi, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|November 10, 2021
Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disordersLusi Zhang, Scot Kristian Hill, Bin Guo, et al.Archives of General Psychiatry|June 10, 2010
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosisLarry J Seidman, Anthony J Giuliano, Eric C Meyer, et al.Archives of General Psychiatry|June 6, 2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE TrialRichard S E Keefe, Robert M Bilder, Sonia M Davis, et al.Nature Medicine|April 2, 2020
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedoniaAndrew D Krystal, Diego A Pizzagalli, Moria Smoski, et al.The Lancet. Psychiatry|November 13, 2025
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trialsRichard S E Keefe, Philip D Harvey, Christoph U Correll, et al.Schizophrenia Research|December 16, 2011
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophreniaDaniel C Javitt, Robert W Buchanan, Richard S E Keefe, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 19, 2021
Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disordersSeenae Eum, S Kristian Hill, Ney Alliey-Rodriguez, et al.Translational Psychiatry|April 13, 2018
Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controlsRebecca Shafee, Pranav Nanda, Jaya L Padmanabhan, et al.Journal of Clinical Psychopharmacology|June 18, 2015
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent SymptomsDeanna L Kelly, Kelli M Sullivan, Joseph P McEvoy, et al.Pageof 24